The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 52 kDa.
Use at an assay dependent concentration.
Use at an assay dependent concentration.
Chromosomal protein that binds to methylated DNA. It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. Mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A.
Present in all adult somatic tissues tested.
Defects in MECP2 may be a cause of Angelman syndrome (AS) [MIM:105830]; also known as happy puppet syndrome. AS is a neurodevelopmental disorder characterized by severe mental retardation, absent speech, ataxia, sociable affect and dysmorphic facial features. AS and Rett syndrome have overlapping clinical features. Defects in MECP2 are the cause of mental retardation syndromic X-linked type 13 (MRXS13) [MIM:300055]. Mental retardation is a mental disorder characterized by significantly sub-average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. MRXS13 patients manifest mental retardation associated with other variable features such as spasticity, episodes of manic depressive psychosis, increased tone and macroorchidism. Defects in MECP2 are the cause of Rett syndrome (RTT) [MIM:312750]. RTT is an X-linked dominant disease, it is a progressive neurologic developmental disorder and one of the most common causes of mental retardation in females. Patients appear to develop normally until 6 to 18 months of age, then gradually lose speech and purposeful hand movements and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation, and stereotypic hand movements. After initial regression, the condition stabilizes and patients usually survive into adulthood. Defects in MECP2 may be the cause of susceptibility autism X-linked type 3 (AUTSX3) [MIM:300496]. AUTSX3 is a pervasive developmental disorder (PDD), prototypically characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Defects in MECP2 are the cause of encephalopathy neonatal severe due to MECP2 mutations (ENS-MECP2) [MIM:300673]. Note=The MECP2 gene is mutated in Rett syndrome, a severe neurodevelopmental disorder that almost always occurs in females. Although it was first thought that MECP2 mutations causing Rett syndrome were lethal in males, later reports identified a severe neonatal encephalopathy in surviving male sibs of patients with Rett syndrome. Additional reports have confirmed a severe phenotype in males with Rett syndrome-associated MECP2 mutations. Defects in MECP2 are the cause of mental retardation syndromic X-linked Lubs type (MRXSL) [MIM:300260]. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. MRXSL patients manifest mental retardation associated with variable features. They include swallowing dysfunction and gastroesophageal reflux with secondary recurrent respiratory infections, hypotonia, mild myopathy and characteristic facies such as downslanting palpebral fissures, hypertelorism and a short nose with a low nasal bridge. Note=Increased dosage of MECP2 due to gene duplication appears to be responsible for the mental retardation phenotype.
Methyl CpG binding protein 2 (Rett syndrome) antibody
Methyl CpG binding protein 2 antibody
Methyl-CpG-binding protein 2 antibody
MRX 16 antibody
MRX 79 antibody
MRXS 13 antibody
WBP 10 antibody
Immunocytochemistry/ Immunofluorescence - Anti-MeCP2 antibody [Mec-168] (ab50005)This image is courtesy of an Abreview submitted by Eike Wegener
ab50005 staining MeCP2 in mouse E15.5 embryo/eye analge by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde, permeabilized with modified citrate buffer pH6.1 and blocked for 30 minutes at 22°C. Samples were incubated with primary antibody (1/100) for 12 hours at 4°C. An Cy3®-conjugated donkey anti-mouse IgG polyclonal (1/1000) was used as the secondary antibody.
Immunocytochemistry/ Immunofluorescence - Anti-MeCP2 antibody [Mec-168] (ab50005)Vecsler M et al., PLoS One. 2011;6(6):e20733. Fig. 4., doi: 10.1371/journal.pone.0020733
Immunofluorescence studies of NB54-treated (D–F) R294X fibroblasts, using MeCP2 C-terminal antibody ab50005. Staining of the full-length MeCP2 (green signal in D, F) corresponds with the DAPI staining (blue signal in E, F), thus indicating its nuclear localization.
Cells were fixed with 4% paraformaldehyde in PBS for 20 min. Permeabilization included incubation with 0.1% Triton X-100 for 5 min and blocking with 5% skimmed milk in TBS containing 0.1% Tween 20 for 30 minutes at room temperature. Incubations with primary antibody ab50005 (1/1000) and secondary antibody Alexa Fluor® 488-conjugated goat anti-mouse (1/500) were performed in blocking solution for 1 hour